TrialInternational journal of hematology2007

Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, Japan.

Emi Matsuo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.